Toronto, Canada – Princess Margaret Cancer Centre researchers have made new findings which provide a broader understanding of how dormant hematopoietic stem cells are activated and could pave the way towards therapeutic treatments for a number of cancers.
The team has made the discovery by performing a deep mechanistic study of lysosomes, which are membrane-bound organelles found in all cells. Lysosomes were once believed to merely be the “garbage bin" of the stem cell, recycling waste material, regulating cellular regeneration and functioning the same in all cell types. But the Princess Margaret (PM) team's research builds on new knowledge about lysosomes which shows they act as key signaling hubs, regulating long-term hematopoietic stem cells.
Work done by the researchers examines why a hematopoietic stem cell can remain dormant for years, and how the lysosome constantly acts as a sensor even in that deeply inactive state. The PM team found that in spite of the cell's dormancy, the lysosome inside it is still very active, “clipping and inactivating" receptors involved in growth signaling and nutrient transport within the stem cell membrane, allowing it to remain asleep.
The findings could have implications beyond the study, potentially allowing for control of the balance between cell dormancy and when stem cells are activated to help replenish the blood supply.
The results come from the laboratory of Princess Margaret Senior Scientist Dr. John Dick and are published in Cell Stem Cell on Aug. 2. Post-doctoral fellow, Dr. Laura Garcia-Prat is first author, and affiliate scientist, Dr. Stephanie Xie, is co-senior author along with Dr. Dick.
“The study has discovered a new mechanism of dormancy, which is to harness an organelle, a lysosome, and keep that cell dormant," says Dr. Garcia-Prat. “This opens a way that lysosomes could potentially be harnessed as a therapeutic target."
Every year, tens of thousands of people around the world receive bone marrow transplants to help fight leukemia. High doses of chemotherapy are used to kill the rapidly dividing cancer cells, but at the same time that also kills stem cells needed to reproduce healthy blood.
Stem cell transplants are used to regenerate a patient's heathy blood supply, but finding a matching donor can be challenging, especially within different ethnic communities where donor lists may not be extensive or exist at all. Stem cells found in cord blood would have considerable value as additional donor sources, but the number of stem cells is often too low for an adult recipient. Understanding how to activate and expand stem cells in a controlled way could make cord blood more widely useful.
Being able to control the activation of stem cells might also be useful for situations where stem cells are inappropriately activated due to disease, inflammation or drug treatment, helping to restore dormancy to conserve these valuable commodities.
“Learning how to conserve, and preserve, blood stem cells is vital," says Dr. Dick. “If that stem cell gets activated in an inappropriate way that can have huge consequences for the blood system because you're now losing your stem cells and you're not going to have that for your lifetime.
“You've got to do everything you can to keep that cell dormant. And one way you do that is by preventing it from sensing any signals from the surface," added Dr. Dick.
The work could also be used to help more fully understand leukemia stem cells which closely mimic regular stem cells and sometimes are able to go dormant and evade treatments.
“Now it will be interesting to look at these leukemia stem cells and see how this mechanism is regulated," says Dr. Xie. “We may see differences and utilize them for treatment."
Dr. Garcia-Prat said this is work could have only done at Dr. Dick's lab at the Princess Margaret Cancer Centre at the University Health Network.
“We are one of the few labs in the world working with human hematopoietic stem cells," says Dr. Garcia-Prat. “So that makes a huge difference in terms of translating our research into therapies for humans."
J.E.D Celgene: research funding; Trillium Therapeutics: Advisory Board. All other authors declare no competing interests.
This work was supported by the Princess Margaret Cancer Centre Foundation, Ontario Institute for Cancer Research, Canadian Institutes for Health Research, International Development Research Centre, Canadian Cancer Society, Terry Fox New Frontiers Program, University of Toronto's Medicine by Design, the Canada First Research Excellence Fund, EMBO Long-Term Fellowship, Benjamin Pearl Fellowship and CIHR Fellowship.
About Princess Margaret Cancer Centre
Princess Margaret Cancer Centre has achieved an international reputation as a global leader in the fight against cancer and delivering personalized cancer medicine. The Princess Margaret, one of the top five international cancer research centres, is a member of the University Health Network, which also includes Toronto General Hospital, Toronto Western Hospital, Toronto Rehabilitation Institute and the Michener Institute for Education at UHN. All are research hospitals affiliated with the University of Toronto. For more information: www.theprincessmargaret.ca
Media contact: Shawn Jeffords, Princess Margaret Cancer Centre, University Health Network (firstname.lastname@example.org).